ASX Announcement

28 June 2022

Webinar presentation on proteomics and disease marker identification in DMD

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] is pleased to announce that the Company has been invited to present at a Science/AAAS webinar titled: **Evaluating a novel antisense oligonucleotide treatment for Duchenne muscular dystrophy: Tracking the impact on multiple plasma proteins** on Wednesday 29 June 2022 @ 8.00 am AEST: Tuesday, 28 June 2022 @ 6.00 pm EDT. Details here.

Dr George Tachas, Director, Drug Discovery & Patents will discuss the results of the Company's successful Phase II study of ATL1102 in non-ambulant patients with DMD and how proteomic analysis with SomaScan® added significantly to the understanding of the modulation of plasma proteins in the patients participating in the study including on known genetic modifiers of DMD progression. Following the webinar the presentation will be available on the Company website https://www.antisense.com.au/presentations/.

As previously announced the Company is undertaking a world first study to assess up to 7,000 plasma proteins in Long COVID-19 patients also using the SomaScan® assay for protein analysis. See announcement here

This announcement has been authorised for release by the CEO.

For more information please contact:

Antisense Therapeutics
Mark Diamond
Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries
Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

US/European IR & Media
Laine Yonker/Joe Green
Edison Investor Relations
lyonker@edisongroup.com
+1 646-653-7035

About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

About ATL1102 ATL1102 is an antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). Antisense inhibition of VLA-4 expression has demonstrated activity in a number of animal models of inflammatory disease including asthma and MS with the MS animal data having been published in a peer reviewed scientific journal. ATL1102 was shown to be highly effective in reducing MS lesions in a Phase IIa clinical trial in patients with RR-MS. The ATL1102 Phase IIa clinical data has been published in the medical Journal ***Neurology*** (Limmroth, V. et al Neurology, 2014; 83(20): 1780-1788). ATL1102 is the only drug targeting CD49d in clinical development for DMD.

About SomaLogic: SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic's personalized measurement of important changes in an individual's proteins over time. SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory. www.somalogic.com